跳至主要内容
临床试验/NCT00880386
NCT00880386撤回不适用

A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients With Non-Small Cell Lung Cancer

University of South Florida0 个研究点开始时间: 2009年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
主要终点
Change in carbon monoxide diffusing capacity (DLCO) at 6 months

研究概览

简要总结

RATIONALE: Losartan potassium may be effective in treating pulmonary fibrosis caused by radiation therapy in patients with non-small cell lung cancer.

PURPOSE: This clinical trial is studying losartan to see how well it works in treating pulmonary fibrosis caused by radiation therapy in patients with stage I, stage II, or stage III non-small cell lung cancer.

详细描述

OBJECTIVES:

Primary

  • To evaluate the effects of losartan potassium on the disease progression in patients with stage I-III non-small cell lung cancer and radiation-induced pulmonary fibrosis.
  • To determine the feasibility of losartan potassium as a possible treatment for radiation-induced pulmonary fibrosis.

Secondary

  • The evaluate the effects of losartan potassium on the degree of dyspnea, and lung function (FEV_1 and FVC) in these patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Losartan Group

Experimental

50 mg Losartan tablet taken daily for 24 weeks

干预措施: Losartan (Drug)

结局指标

主要结局

Change in carbon monoxide diffusing capacity (DLCO) at 6 months

时间窗: 6 months

次要结局

  • Feasibility of losartan potassium as treatment for radiation-induced pulmonary fibrosis(6 months)
  • Pulmonary function measurements of FEV1 and FVC and dyspnea score at 6 months(6 months)

研究者

申办方类型
Other
责任方
Sponsor

相似试验